PharmaCyte Biotech, Inc.
Datakwaliteit: 100%
PMCB
Nasdaq
Manufacturing
Chemicals
€ 0,68
▲
€ 0,00
(0,31%)
Marktkapitalisatie: 7,34 M
Prijs
€ 0,68
Marktkapitalisatie
7,34 M
Dagbereik
€ 0,67 — € 0,72
52-Weeksbereik
€ 0,63 — € 1,51
Volume
69.145
Openen € 0,72
50D / 200D Gem.
€ 0,73
6,82% below
50D / 200D Gem.
€ 0,89
23,46% below
Quick Summary
Belangrijkste Punten
Earnings grew 9084,98% over the past year
Negative free cash flow of -4,80 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)9084,98%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-8,95%
Boven sectorgemiddelde (-53,41%)
ROIC-7,83%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio12,33
Interest CoverageN/A
Waardering
PE (TTM)
-2,24
Onder sectorgemiddelde (-1,48)
P/B Ratio0,19
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,2 | -1,5 |
| P/B | 0,2 | 1,6 |
| ROE % | -9,0 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | 9084,98% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -3,28 M |
| ROE | -8,95% | ROA | -5,87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -4,80 M |
| ROIC | -7,83% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 12,33 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | 19,02 M | Tangible Book Value | 36,56 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,24 | Forward P/E | N/A |
| P/B Ratio | 0,19 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -65,43% | ||
| Market Cap | 7,34 M | Enterprise Value | -12,83 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,89 | Revenue / Share | 0,00 |
| FCF / Share | -0,45 | OCF / Share | -0,45 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 146,29% |
| SBC-Adj. FCF | -5,77 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Net Income | 30,66 M | 333.763,0 | -4,32 M | -4,24 M | -3,55 M |
| EPS (Diluted) | 3,19 | -1,80 | -0,22 | -0,27 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -4,38 M | -8,52 M | -6,46 M | -4,39 M | -3,62 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 438.416,0 | 407.431,0 | 468.536,0 | 690.937,0 | 916.249,0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 0,0 | 509,0 | 3.046,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 55,17 M | 59,90 M | 73,28 M | 90,62 M | 7,40 M |
| Total Liabilities | 3,28 M | 20,39 M | 586.581,0 | 704.370,0 | 724.778,0 |
| Shareholders' Equity | 51,89 M | 27,65 M | 72,69 M | 89,92 M | 6,68 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 15,17 M | 50,18 M | 68,04 M | — | — |
| Current Assets | 22,38 M | 50,44 M | 68,15 M | 85,49 M | 2,28 M |
| Current Liabilities | 2,91 M | 7,42 M | 586.581,0 | 704.370,0 | 724.778,0 |
{"event":"ticker_viewed","properties":{"ticker":"PMCB","listing_kind":"stock","pathname":"/stocks/pmcb","exchange":"Nasdaq","country":"US"}}